Cystic Fibrosis Related Diabetes Needs New Treatment Approaches, Researchers Say

Cystic fibrosis related diabetes, or CFRD, is a form of diabetes that develops in people with cystic fibrosis. It differs from Type 1 and Type 2 diabetes, though it shares some genetic and biological features with both. Because CFRD affects everyone with cystic fibrosis at some point in their life, regular screening is important for those who haven't developed it yet, and proper management is essential for those who have.

As the CF population ages—thanks to better treatments and longer lifespans—the number of people developing CFRD is expected to grow. This makes understanding and treating the condition increasingly urgent.

In recent years, highly effective CFTR modulators have transformed treatment for cystic fibrosis, dramatically improving lung function for many patients. These drugs work by fixing the faulty CFTR protein that causes CF. Researchers hoped that by treating CF so effectively early on, CFRD might be delayed or even prevented.

However, studies so far show that these new CF medications haven't significantly reduced the rates at which people develop CFRD. This finding underscores the need for research specifically targeting CFRD, rather than assuming that treating the underlying CF alone will solve the diabetes problem.

At the 20th European Cystic Fibrosis Society Basic Science conference, researchers highlighted three promising areas of investigation.

First, scientists are studying genetic and non-genetic risk factors for CFRD to better understand how the disease develops and to improve the ability to predict who will develop it. This knowledge could help doctors identify high-risk patients earlier and tailor prevention strategies.

Second, researchers are examining how diet and body composition affect CFRD management. Optimizing nutrition may play an important role in controlling the condition and reducing its impact on overall health.

Third, scientists are adapting advances from Type 1 diabetes research—including stem cell approaches and 'organ on chip' laboratory models that simulate how the pancreas works—to better understand and treat CFRD. These cutting-edge tools may reveal new targets for treatment and accelerate the development of therapies.

With current CF treatments not yet solving the CFRD problem, the research community is focused on accelerating studies with direct benefits for patients. The combination of genetic insights, dietary optimization, and advances borrowed from Type 1 diabetes research represents a multi-pronged approach to addressing a condition that affects virtually everyone with cystic fibrosis.

As the CF population continues to age and CFRD becomes even more prevalent, this research will become increasingly important for maintaining quality of life and long-term health.

Source: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.